H1B Salary Data

Home › Employers › Actym Therapeutics, Inc.

Actym Therapeutics, Inc.: H-1B salaries and sponsorship

Actym Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $136,423.

Applications (LCAs)3
Certified2
Employer addressBerkeley, CA
H-1B dependent employerNo
Median offered salary$136,423
Middle half of salaries$111,212–$161,634
10th–90th percentile$96,085–$176,761

Does Actym Therapeutics, Inc. sponsor H-1B visas?

Actym Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 9, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Associate Director, CMC and Bioanalystical2$186,846
Research Associate II1$86,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20232$186,846
FY20251$86,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Research Associate II$86,000–$96,000
Level I
Berkeley, CAApr 9, 2025Oct 1, 2025Certified
Associate Director, CMC and Bioanalystical$186,846–$200,000
Level IV
Berkeley, CAAug 17, 2023Aug 21, 2023Certified
Associate Director, CMC and Bioanalystical$186,846–$200,000
Level IV
Berkeley, CAAug 15, 2023Aug 21, 2023Denied

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).